Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Lo studio nazionale finlandese per facilitare l'accesso dei pazienti a farmaci antitumorali mirati (FINPROVE)

9 novembre 2026 aggiornato da: Katriina Jalkanen, Helsinki University Central Hospital

Lo studio nazionale finlandese per facilitare l'accesso dei pazienti a farmaci antitumorali mirati per determinare l'efficacia nel trattamento dei tumori avanzati con un profilo molecolare noto

This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This is a prospective non-randomized clinical trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test. The study also aims to facilitate patient access to approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies and to perform next generation sequencing and further deeper analysis on tumor biopsies and/or liquid biopsies for biomarker analyses and resistance mechanisms. Eligible patients have an advanced cancer for which standard treatment options no longer exist and acceptable performance status and organ function. A tumour DNA, RNA or protein expression analysis is required and the results must identify at least one potentially actionable molecular variant as defined in the protocol. Molecular profiling will be utilized to determine an appropriate drug(s) from among those available in the protocol. Drug selection will be guided by a list of potential profiles, the molecular tumor board and databases of identified targets for review and approval of the recommended treatment. The protocol-specified treatment will be administered to the patient once any drug- and disease specific eligibility criteria and overall study criteria are met. Data for standard efficacy outcomes including tumor response, progression-free and overall survival as well as duration of treatment will be collected for all patients receiving treatment within the trial. In addition, treatment related toxicity will be collected according to CTCAE 5.0.

Tipo di studio

Interventistico

Iscrizione (Stimato)

250

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Kuopio, Finlandia
        • Reclutamento
        • Kuopio University Hospital
        • Contatto:
          • Okko Kääriäinen, MD
      • Oulu, Finlandia
        • Reclutamento
        • Oulu University Hospital OYS Cancer Center
        • Contatto:
          • Sanna Iivanainen, MD. PhD.
      • Tampere, Finlandia
        • Reclutamento
        • Tampere University Hospital Department of Oncology
        • Contatto:
          • Minna Tanner, MD, PhD
    • Southwest Finland
      • Turku, Southwest Finland, Finlandia
        • Reclutamento
        • Turku University Hospital Cancer Centre
        • Contatto:
          • Erika Alanne, MD, PhD
    • Uusimaa
      • Helsinki, Uusimaa, Finlandia, 00029
        • Reclutamento
        • Helsinki University Hospital Comprehensive Cancer Center
        • Contatto:
          • Tanja Juslin
        • Investigatore principale:
          • Katriina Jalkanen, MD, PhD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 100 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Adult (age >18 years) patient with a histologically-confirmed locally advanced or metastatic cancer who is no longer benefitting from standard anti-cancer treatment or for whom no such treatment is available or indicated.

  2. ECOG performance status 0-2

  3. Patients must have acceptable organ function as defined below. However, specific inclusion/exclusion criteria specified in the drug-specific study manual will take precedence:

    1. Absolute neutrophil count ≥ 1.5 x 109/l
    2. Hemoglobin > 8.0 mmol/l, without blood transfusion within 7 days
    3. Platelets > 75 x 109/l (not applicable for hematological patients)
    4. Total bilirubin < 1.5 x ULN
    5. AST and ALT < 3 x institutional ULN (or < 5 x ULN in patients with known hepatic metastases)
    6. Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 40 mL/min/1.73 m2
  4. Patients must have objectively evaluable or measurable disease (by physical or radiographic examination, according to RECIST v1.1, Lugano, IWG and ELN-AML, IMWG, RANO, GCIG, iRESIST or PCWG3.

  5. Results must be available from a tumor molecular profiling. Eligible tests may include any of the following technologies: fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), comparative genomic hybridization (CGH), next generation sequencing (NGS) or immunohistochemistry (IHC). The test may have been performed on the primary tumor or a metastatic lesion, in a diagnostic laboratory or within the context of another commercial platform (eg Foundation Medicine), and must reveal a potentially actionable variant.

  6. Patients must have a tumor profile for which treatment with one of the approved (or under revision for approval) targeted anti-cancer drugs included in this study has potential clinical benefit based on preclinical data or clinical information.

  7. A new (obtained ≤6 months before inclusion after which no further anti-cancer therapy is allowed) fresh frozen and FFPE tumor biopsy specimen or liquid biopsy for extensive biomarker testing is mandatory before the start of treatment with a targeted agent included in the protocol.

  8. Ability to understand and the willingness to sign a written informed consent document and comply to the protocol.

  9. For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.

  10. Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Male patients should avoid impregnating a female partner. Male patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or completely abstain from sexual intercourse.

Exclusion Criteria:

  1. Ongoing toxicity > grade 2, other than alopecia or > grade 1 neuropathy.

  2. Patient is receiving any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement). Required wash out period prior to starting study treatment is at least two weeks. An exception is made for:

    1. Patients suffering from CRPC are allowed to continue androgen deprivation therapy.
    2. Medications that are prescribed for supportive care but may potentially have an anti-cancer effect (e.g., megestrol acetate, bisphosphonates). These medications must have been started ≥ 1 week prior to enrollment on this study.
  3. Received colony-stimulating factors (eg, G-CSF, GM-CSF or recombinant EPO) within 14 days prior to the first dose of study intervention

  4. Patient is pregnant or nursing.

  5. Patients with known active progressive brain metastases. Patients with previously treated brain metastases are eligible, provided that the patient is clinically stable and off steroids for at least 4 weeks prior to study initiation. GMB patients apply additional exclusion criteria.

  6. Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible.

  7. Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible.

  8. Patients with known left ventricular ejection fraction (LVEF) < 45% are not eligible

  9. Patients with stroke (including TIA) or acute myocardial infarction within 3 months before the first dose of study treatment are not eligible

  10. Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements including, but not limited to: ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness/social situations.

For each drug included in this protocol, specific inclusion and exclusion criteria (based on the Package Insert or manufacturers recommendations) may also apply. Drug-specific inclusion and exclusion criteria will take precedence over the inclusion/exclusion criteria listed above.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Alectinib

For patients with a molecular tumor profile that can potentially be targeted by alectinib.

ALK

Altri nomi:
  • Alecensa
Sperimentale: Cobimetinib

For patients with a molecular tumor profile that can potentially be targeted by cobimetinib.

MEK1, MEK2

Altri nomi:
  • Cotellico
Sperimentale: Vismodegib

For patients with a molecular tumor profile that can potentially be targeted by vismodegib.

Hedgehog

Altri nomi:
  • Erivedge
Sperimentale: Trastuzumab+Pertuzumab

For patients with a molecular tumor profile that can potentially be targeted by trastuzumab+pertuzuma combination.

HER2

Altri nomi:
  • Phesgo
Sperimentale: Entrectinib

For patients with a molecular tumor profile that can potentially be targeted by entrectinib.

NTRK/ ROS1, ALK

Altri nomi:
  • Rozlytrek
Sperimentale: Atezolizumab

For patients with a molecular tumor profile that can potentially be targeted by atezolizumab.

PD-L1

Altri nomi:
  • Tecentriq
Sperimentale: Vemurafenib

For patients with a molecular tumor profile that can potentially be targeted by vemurafenib.

BRAF V600

Altri nomi:
  • Zelboraf
Sperimentale: Regorafenib

For patients with a molecular tumor profile that can potentially be targeted by regorafenib.

KIT/BRAF, RET

Altri nomi:
  • Stivarga
Sperimentale: Apalutamide

For patients with a molecular tumor profile that can potentially be targeted by apalutamide.

AR

Altri nomi:
  • Erleada
Sperimentale: Abemaciclib

For patients with a molecular tumor profile that can potentially be targeted by abemaciclib.

CDK4/6

Altri nomi:
  • Verzenio
Sperimentale: Tepotinib

For patients with a molecular tumor profile that can potentially be targeted by tepotinib.

MET ex14

Altri nomi:
  • Tepmetko
Sperimentale: Dabrafenib

For patients with a molecular tumor profile that can potentially be targeted by dabrafenib.

RAF

Altri nomi:
  • Tafinlar
Sperimentale: Trametinib

For patients with a molecular tumor profile that can potentially be targeted by trametinib.

MEK1, MEK2

Altri nomi:
  • Mekinista
Sperimentale: Dabrafenib+Trametinib

For patients with a molecular tumor profile that can potentially be targeted by dabrafenib+trametinib combination.

RAF, MEK1, MEK2

Altri nomi:
  • Tafinlanr+Mekinist
Sperimentale: Pemigatinib

For patients with a molecular tumor profile that can potentially be targeted by pemigatinib.

FGFR2

Altri nomi:
  • Pemazire

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Disease control rate
Lasso di tempo: 16 weeks

Disease control rate at 16 weeks after treatment initiation (defined as patients by CR, PR, SD)

16 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Duration of treatment
Lasso di tempo: 5 years

Time on drug

5 years
Adverse Events
Lasso di tempo: 5 years

Treatment-related grade ≥3 and serious adverse events

5 years
Overall response
Lasso di tempo: 5 years

Best overall response (defined as patients by CR, PR, SD)

5 years
PFS
Lasso di tempo: 5 years

Progression free survival

5 years
OS
Lasso di tempo: 5 years

Overall survival

5 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Katriina Jalkanen, MD, PhD, Helsinki University Hospital Comprehensive Cancer Centre

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

10 dicembre 2021

Completamento primario (Stimato)

25 novembre 2031

Completamento dello studio (Stimato)

25 novembre 2032

Date di iscrizione allo studio

Primo inviato

3 dicembre 2021

Primo inviato che soddisfa i criteri di controllo qualità

3 dicembre 2021

Primo Inserito (Effettivo)

16 dicembre 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Altri numeri di identificazione dello studio

  • FINPROVE

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Investigators plan to share the clinical study report.

Periodo di condivisione IPD

2026-2027

Criteri di accesso alla condivisione IPD

Will be made available through European regulatory CTIS programme.

Tipo di informazioni di supporto alla condivisione IPD

  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .